These side effects had been notably milder when compared to an inhibitor of both of those bromodomains. An in depth molecular Examination also unveiled that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes.  ― Stephen Taylor 88 These preclinical studies provide paradigms for future clinical trials in AML, https://franciscoshuix.newsbloger.com/32670081/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained